Status:

ACTIVE_NOT_RECRUITING

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

Lead Sponsor:

AbbVie

Conditions:

Crohn's Disease (CD)

Eligibility:

All Genders

18-80 years

Phase:

PHASE3

Brief Summary

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab. This study will...

Eligibility Criteria

Inclusion

  • Confirmed diagnosis of Crohn's disease (CD) for at least 3 months prior to Baseline.
  • Crohn's disease activity index (CDAI) score 220 - 450 at Baseline.
  • Confirmed diagnosis of moderate to severe Crohn's Disease as assessed by stool frequency (SF), abdominal pain (AP) score, and Simple Endoscopic score for CD (SES-CD).
  • Demonstrated intolerance or inadequate response to one or more anti-tumor necrosis factor (TNF) therapies.

Exclusion

  • Current diagnosis of ulcerative colitis or indeterminate colitis.
  • Receipt of CD approved biologic agents prior to Baseline (as detailed in protocol), or any investigational biologic or other agent or procedure prior to Baseline (as detailed in protocol).
  • Prior exposure to p19 and/or p40 inhibitors (e.g., risankizumab and ustekinumab).
  • Currently know complications of CD (strictures, short bowel, etc).

Key Trial Info

Start Date :

September 30 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2028

Estimated Enrollment :

527 Patients enrolled

Trial Details

Trial ID

NCT04524611

Start Date

September 30 2020

End Date

February 1 2028

Last Update

August 12 2025

Active Locations (300)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 75 (300 locations)

1

Advanced Gastroenterology, P.C /ID# 224396

Chandler, Arizona, United States, 85224-1636

2

Southern California Res. Ctr. /ID# 223484

Coronado, California, United States, 92118-1408

3

Hoag Memorial Hosp Presbyterian /ID# 224373

Irvine, California, United States, 92618

4

United Medical Doctors /ID# 223486

Los Alamitos, California, United States, 90720-3309

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) | DecenTrialz